Insider Buying: Oncolytics Biotech (TSE:ONC) Insider Purchases 12,000 Shares of Stock

Oncolytics Biotech Inc. (TSE:ONC) insider Kirk Look purchased 12,000 shares of Oncolytics Biotech stock in a transaction that occurred on Thursday, February 12th. The shares were bought at an average cost of C$1.16 per share, for a total transaction of C$13,920.00. Following the transaction, the insider directly owned 171,465 shares of the company’s stock, valued at C$198,899.40. This represents a 7.53% increase in their ownership of the stock.

Oncolytics Biotech Price Performance

The company’s 50 day moving average price is C$14.90 and its 200 day moving average price is C$13.02. Oncolytics Biotech Inc. has a 1 year low of C$0.44 and a 1 year high of C$2.08. The firm has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75.

Oncolytics Biotech (TSE:ONC) last released its quarterly earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share for the quarter. On average, analysts expect that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.